EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Isomaltulose (Palatinose ®) e controle glicêmico: evidências científicas e perspectivas para a terapia nutricional hospitalar

Leonardo Barbosa Guerreiro, Getúlio José do Carmo Neves Neto, Alexandre Victor de Oliveira Barata Pinheiro, William Robert de Souza Souza, Naira Cristina Carmo Mercês, Pedro Henrique Costa da Cruz, Fábio Costa de Vasconcelos

Revista ft · 23.10.2026 · 30 (163) · 01-11

DOI: 10.69849/akh5mt60 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista ft, online erschienen am 23.10.2026. Verfasst von Leonardo Barbosa Guerreiro und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to analyze the scientific evidence regarding the effects of isomaltulose (Palatinose®) on glycemic control and glycemic variability in adults across different clinical contexts, with emphasis on nutritional therapy for critically ill patients. This is an integrative literature review conducted using the PubMed, SciELO, Cochrane Library, Taylor & Francis Online, and CAPES Journals Portal databases. Three clinical studies in humans were analyzed, investigating the use of isomaltulose in patients with postoperative hyperglycemia, type 2 diabetes mellitus undergoing elective surgery, and diabetes mellitus associated with esophageal cancer. The results indicated potential benefits, including reductions in mean blood glucose levels, glycemic peaks, and the frequency of hyperglycemic episodes, as well as lower glycemic variability in one of the studies and a reduced need for adjustments to insulin therapy in the cases described. These effects may be related to the slower hydrolysis of isomaltulose, which promotes the gradual release of glucose and fructose. However, the small number of studies and participants, methodological heterogeneity, and the lack of direct assessment of glycemic variability in all investigations limit the generalizability of the findings. It is concluded that Palatinose® has potential as an adjunct nutritional strategy for glycemic control; however, more robust clinical studies are needed to establish its efficacy and applicability in critically ill patients.

Zitieren

APA

Guerreiro, L. B., Neto, G. J. D. C. N., Pinheiro, A. V. D. O. B., Souza, W. R. D. S., Mercês, N. C. C., Cruz, P. H. C. D., & Vasconcelos, F. C. D. (2026). Isomaltulose (Palatinose ®) e controle glicêmico: evidências científicas e perspectivas para a terapia nutricional hospitalar. Revista ft, 30(163), 01-11. https://doi.org/10.69849/akh5mt60

Vancouver

Guerreiro LB, Neto GJDCN, Pinheiro AVDOB, Souza WRDS, Mercês NCC, Cruz PHCD, et al. Isomaltulose (Palatinose ®) e controle glicêmico: evidências científicas e perspectivas para a terapia nutricional hospitalar. Revista ft. 2026;30(163):01-11. doi:10.69849/akh5mt60

BibTeX
@article{Guerreiro2026,
  author = {Guerreiro, Leonardo Barbosa and Neto, Getúlio José do Carmo Neves and Pinheiro, Alexandre Victor de Oliveira Barata and Souza, William Robert de Souza and Mercês, Naira Cristina Carmo and Cruz, Pedro Henrique Costa da and Vasconcelos, Fábio Costa de},
  title = {Isomaltulose (Palatinose ®) e controle glicêmico: evidências científicas e perspectivas para a terapia nutricional hospitalar},
  journal = {Revista ft},
  year = {2026},
  volume = {30},
  number = {163},
  pages = {01--11},
  doi = {10.69849/akh5mt60}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche